Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer
出版年份 2022 全文链接
标题
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer
作者
关键词
HER2-positive breast cancer, HER2DX, Gene expression, Immune, Prognosis, Pathological complete response, Neoadjuvant, Risk of relapse, De-escalation
出版物
EBioMedicine
Volume 75, Issue -, Pages 103801
出版商
Elsevier BV
发表日期
2022-01-04
DOI
10.1016/j.ebiom.2021.103801
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
- (2021) Francesco Schettini et al. npj Breast Cancer
- Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials
- (2021) Rosie Bradley et al. LANCET ONCOLOGY
- ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6
- (2021) M. Filipits et al. ESMO Open
- Dissecting the biological heterogeneity of HER2-positive breast cancer
- (2021) Francesco Schettini et al. BREAST
- Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial
- (2021) Amy S. Clark et al. Nature Communications
- HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis
- (2020) Francesco Schettini et al. CANCER TREATMENT REVIEWS
- HER2-Low Breast Cancer: Pathological and Clinical Landscape
- (2020) Paolo Tarantino et al. JOURNAL OF CLINICAL ONCOLOGY
- Biomarker data from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer.
- (2020) Carsten Denkert et al. JOURNAL OF CLINICAL ONCOLOGY
- ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer
- (2020) Gaia Griguolo et al. Cancers
- Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer
- (2020) Aranzazu Fernandez-Martinez et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer
- (2019) M V Dieci et al. ANNALS OF ONCOLOGY
- Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
- (2019) Sara M. Tolaney et al. JOURNAL OF CLINICAL ONCOLOGY
- Genomic correlates of response to adjuvant trastuzumab (H) and pertuzumab (P) in HER2+ breast cancer (BC): Biomarker analysis of the APHINITY trial.
- (2019) Ian E. Krop et al. JOURNAL OF CLINICAL ONCOLOGY
- HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade
- (2019) Aleix Prat et al. JNCI-Journal of the National Cancer Institute
- 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial
- (2019) Helena M Earl et al. LANCET
- 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial
- (2019) Xavier Pivot et al. LANCET
- Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
- (2018) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
- (2018) Heikki Joensuu et al. JAMA Oncology
- 9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study
- (2018) P Conte et al. ANNALS OF ONCOLOGY
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
- (2018) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial
- (2017) Antonio Llombart-Cussac et al. LANCET ONCOLOGY
- Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Miguel Martin et al. LANCET ONCOLOGY
- Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
- (2017) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy
- (2017) Debora Fumagalli et al. JAMA Oncology
- Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1)vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer
- (2016) Sung-Bae Kim et al. INTERNATIONAL JOURNAL OF CANCER
- Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial
- (2016) Martine Piccart-Gebhart et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib
- (2016) Lisa A. Carey et al. JOURNAL OF CLINICAL ONCOLOGY
- Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group
- (2016) Carsten Denkert et al. MODERN PATHOLOGY
- 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
- (2016) Fatima Cardoso et al. NEW ENGLAND JOURNAL OF MEDICINE
- A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers
- (2016) Anthony Ferrari et al. Nature Communications
- Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)
- (2015) D. Mavroudis et al. ANNALS OF ONCOLOGY
- Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab
- (2015) Roberto Salgado et al. JAMA Oncology
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
- (2014) R. Salgado et al. ANNALS OF ONCOLOGY
- Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples
- (2014) Timothy R. Wilson et al. BREAST CANCER RESEARCH AND TREATMENT
- Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer
- (2014) Aleix Prat et al. JNCI-Journal of the National Cancer Institute
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
- (2012) Christina Curtis et al. NATURE
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More